Business Context and Reporting Period
Company: Humacyte, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2026
Event: Entry into a Material Definitive Agreement for a registered direct offering of common stock.
Key Financial Metrics
- Offering Size: 25,000,000 shares of Common Stock.
- Offering Price: $0.80 per share.
- Gross Proceeds: $20,000,000 (calculated).
- Net Proceeds: Approximately $18,400,000 (after deducting placement agent fees and estimated expenses).
- Placement Agent: Titan Partners Group LLC (a division of American Capital Partners, LLC).
- Expected Closing Date: On or about March 20, 2026.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations. It solely reports on the capital raise transaction.
Material Changes
The filing reports a material change in the company's capital structure through the issuance of new equity. The company entered into Securities Purchase Agreements to sell 25 million shares at $0.80 per share. This transaction represents a dilution of existing shareholders and an increase in cash liquidity pending the closing of the offering.
Guidance, Outlook, and Risks
- Outlook: The company expects to close the offering on or about March 20, 2026, subject to customary closing conditions.
- Regulatory Status: The offering is made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-290231), declared effective on September 22, 2025.
- Risks/Contingencies: Closing is contingent upon the satisfaction of customary conditions. The filing includes standard representations, warranties, and indemnification obligations.
- Management Commentary: No specific operational guidance or commentary on future performance is included in this text; the focus is strictly on the transaction mechanics.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 20, 2026).
- Confirm the exact amount of net proceeds received after all fees and expenses are finalized.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Check subsequent filings for the impact of this dilution on the company's cash runway and operational plans.
- Review the press release (Exhibit 99.1) for any additional context on the use of proceeds not detailed in the 8-K.